Opportunity Information: Apply for RFA DA 15 017
Apply for RFA DA 15 017
- The National Institutes of Health in the education health sector is offering a public funding opportunity titled "NIDA Translational Avant Garde Award for Development of Medication to Treat Substance Use Disorders (UH2/UH3)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.279 Drug Abuse and Addiction Research Programs.
- This funding opportunity was created on Jan 16, 2015 and posted on Jan 16, 2015.
- Applicants must submit their applications by Apr 15, 2015. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- The funding agency has allocated a total of $3,000,000.00 to eligible and selected applicants.
- Each selected applicant is eligible to receive up to $1,000,000.00 in funding.
- The number of recipients for this funding is limited to 3 candidate(s).
- Eligible applicants include: Public and State controlled institutions of higher education Public housing authorities/Indian housing authorities State governments For profit organizations other than small businesses City or township governments Native American tribal organizations (other than Federally recognized tribal governments) Private institutions of higher education Others (see text field entitled Additional Information on Eligibility for clarification) Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education Special district governments Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education Small businesses County governments Native American tribal governments (Federally recognized) Independent school districts.
- Other Eligible Applicants include the following Alaska Native and Native Hawaiian Serving Institutions Asian American Native American Pacific Islander Serving Institutions (AANAPISISs) Eligible Agencies of the Federal Government Faith based or Community based Organizations Hispanic serving Institutions Historically Black Colleges and Universities (HBCUs) Indian/Native American Tribal Governments (Other than Federally Recognized) Non domestic (non U.S.) Entities (Foreign Organizations) Regional Organizations Tribally Controlled Colleges and Universities (TCCUs) U.S. Territory or Possession.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
The NIDA Translational Avant Garde Award for Development of Medication to Treat Substance Use Disorders (UH2/UH3) is a National Institutes of Health cooperative agreement funding opportunity designed to move promising addiction-treatment medications forward along the drug development pathway. The central aim is translation: NIDA is looking for outstanding basic and/or clinical researchers who can take research discoveries and turn them into viable medication candidates for Substance Use Disorders (SUDs). The targeted SUD areas include disorders stemming from tobacco, cannabis, cocaine, methamphetamine, heroin, and prescription opioid use. A key expectation is that applicants already have, or can credibly generate, molecules with real therapeutic potential and can demonstrate the practical capability to optimize and advance those molecules through the development continuum, with the long-term objective of getting candidates closer to FDA approval.
The award structure uses a two-phase UH2/UH3 model that is explicitly milestone-driven. The first phase (UH2) provides up to two years of support to complete defined, objective milestones that de-risk and advance a medication candidate. Investigators must propose clear UH2 milestones and a plan that shows how those milestones position the project for the next stage. Projects that successfully meet UH2 milestones are then administratively considered by NIDA for transition into the second phase (UH3). The UH3 phase can provide up to three additional years of funding to continue the work, typically focused on more advanced development steps such as lead optimization, IND-enabling activities, and/or progress toward clinical testing, depending on where the candidate sits in the pipeline. Importantly, applications are expected to address both phases up front, meaning applicants need to present an integrated plan that starts with early advancement in UH2 and continues into later-stage activities in UH3 if the project clears the milestone gate.
Because this is a cooperative agreement, NIDA is positioned to have substantial involvement beyond simply providing funds. In practice, that generally means closer coordination around project goals, milestone assessment, and programmatic priorities, reflecting NIDA's interest in building a stronger and broader pipeline of medications for addiction treatment. The opportunity is aimed at attracting exceptionally talented investigators who can contribute novel leads, expand the diversity of candidate molecules, and push those leads toward clinical readiness rather than stopping at basic discovery.
From an administrative and funding standpoint, the opportunity is listed under Funding Opportunity Number RFA-DA-15-017 and falls under CFDA 93.279 (Drug Abuse and Addiction Research Programs). It was posted January 16, 2015, with an original and current closing date of April 15, 2015, and an archive date of May 16, 2015. NIDA anticipated making about three awards, with an estimated total funding level of $3,000,000 and an award ceiling of $1,000,000. There is no cost sharing or matching requirement noted for this program.
Eligibility is broad and includes many organization types across academia, government, nonprofit, and industry. Eligible applicants include public and private institutions of higher education, state and local governments (including counties, cities, townships, and special districts), tribal governments and tribal organizations (including federally recognized and other than federally recognized), public housing authorities/Indian housing authorities, independent school districts, nonprofits (including 501(c)(3) and certain non-501(c)(3) entities), and for-profit organizations other than small businesses, as well as small businesses. The eligibility list also explicitly includes various mission-focused institutions and organizations such as HBCUs, Hispanic-serving institutions, AANAPISI institutions, Alaska Native and Native Hawaiian-serving institutions, tribally controlled colleges and universities, faith-based or community-based organizations, eligible federal agencies, U.S. territories or possessions, regional organizations, and non-U.S. entities (foreign organizations). Overall, the program is structured to bring a wide range of capable drug-development performers into addiction medication translation, provided they can demonstrate the scientific and operational capacity to move a candidate toward the clinic.
For full details, the announcement link provided is http://grants.nih.gov/grants/guide/rfa-files/RFA-DA-15-017.html, and the contact for access or technical issues is the NIH Office of Extramural Research webmaster at FBOWebmaster@OD.NIH.GOV.
FAQs: NIDA Translational Avant Garde Award for Development of Medication to Treat Substance Use Disorders (UH2/UH3)
What is this funding opportunity?
This opportunity is the NIDA Translational Avant Garde Award for Development of Medication to Treat Substance Use Disorders (UH2/UH3), a National Institutes of Health (NIH) cooperative agreement focused on moving promising addiction-treatment medications forward along the drug development pathway.
What is the main goal of the program?
The central aim is translation: supporting outstanding basic and/or clinical researchers who can take research discoveries and turn them into viable medication candidates for Substance Use Disorders (SUDs), with a long-term objective of getting candidates closer to FDA approval.
What types of Substance Use Disorders are targeted?
The targeted SUD areas include disorders stemming from tobacco, cannabis, cocaine, methamphetamine, heroin, and prescription opioid use.
What stage of research and development is NIDA trying to support?
The program is designed for projects that can advance a medication candidate through the development continuum, beyond basic discovery, toward clinical readiness. It emphasizes practical steps that move candidates along the drug development pathway.
Do applicants need to already have a molecule or medication candidate?
A key expectation is that applicants already have, or can credibly generate, molecules with real therapeutic potential and can show practical capability to optimize and advance those molecules through development.
What does the UH2/UH3 structure mean?
The award uses a two-phase model that is explicitly milestone-driven. UH2 is the first phase (up to two years). UH3 is the second phase (up to three additional years) for projects that meet UH2 milestones and are administratively considered by NIDA for transition.
How long can the UH2 phase last, and what is it meant to accomplish?
UH2 can provide up to two years of support to complete defined, objective milestones that de-risk and advance a medication candidate. Applicants must propose clear UH2 milestones and explain how meeting them positions the project for the next stage.
How does a project transition from UH2 to UH3?
Projects that successfully meet the UH2 milestones may be administratively considered by NIDA for transition into UH3. The transition is gated by milestone achievement.
How long can the UH3 phase last, and what kinds of activities may it support?
UH3 can provide up to three additional years of funding for more advanced development steps such as lead optimization, IND-enabling activities, and/or progress toward clinical testing, depending on where the candidate sits in the pipeline.
Do applicants need to address both phases in the application?
Yes. Applications are expected to address both UH2 and UH3 up front, presenting an integrated plan that begins with early advancement in UH2 and continues into later-stage activities in UH3 if the milestone gate is cleared.
What does it mean that this is a cooperative agreement?
As a cooperative agreement, NIDA is expected to have substantial involvement beyond providing funds. This typically includes closer coordination around project goals, milestone assessment, and alignment with programmatic priorities.
What is NIDA hoping to build through this program?
NIDA is aiming to build a stronger and broader pipeline of medications for addiction treatment by attracting exceptionally talented investigators who can contribute novel leads, expand the diversity of candidate molecules, and push those leads toward clinical readiness.
What is the Funding Opportunity Number (FOA)?
The Funding Opportunity Number is RFA-DA-15-017.
What CFDA program does this fall under?
This opportunity falls under CFDA 93.279 (Drug Abuse and Addiction Research Programs).
When was this opportunity posted, and what were the key dates?
It was posted on January 16, 2015. The original and current closing date was April 15, 2015, and the archive date was May 16, 2015.
How many awards did NIDA anticipate making?
NIDA anticipated making about three awards.
What was the estimated total funding amount and award ceiling?
The estimated total funding level was $3,000,000, and the award ceiling was $1,000,000.
Is cost sharing or matching required?
No cost sharing or matching requirement is noted for this program.
Who is eligible to apply?
Eligibility is broad and includes many organization types across academia, government, nonprofit, and industry. Eligible applicants include public and private institutions of higher education; state and local governments (including counties, cities, townships, and special districts); tribal governments and tribal organizations; public housing authorities/Indian housing authorities; independent school districts; nonprofits (including 501(c)(3) and certain non-501(c)(3) entities); for-profit organizations (including small businesses and for-profits other than small businesses); eligible federal agencies; U.S. territories or possessions; regional organizations; and non-U.S. entities (foreign organizations).
Are minority-serving institutions and community-based organizations included in the eligibility list?
Yes. The eligibility list explicitly includes mission-focused institutions and organizations such as HBCUs, Hispanic-serving institutions, AANAPISI institutions, Alaska Native and Native Hawaiian-serving institutions, tribally controlled colleges and universities, and faith-based or community-based organizations.
Does the opportunity allow applications from non-U.S. organizations?
Yes. The eligibility list explicitly includes non-U.S. entities (foreign organizations).
Where can applicants find the full announcement?
The announcement link provided is http://grants.nih.gov/grants/guide/rfa-files/RFA-DA-15-017.html
Who should be contacted for access or technical issues with the announcement?
The contact for access or technical issues is the NIH Office of Extramural Research webmaster at FBOWebmaster@OD.NIH.GOV.
Browse more opportunities from the same category: Education Health
Next opportunity: National Fetal, Infant and Child Death Review Center Program
Previous opportunity: Intramural NIGMS Postdoctoral Research Associate (PRAT) Program (FI2)
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for RFA DA 15 017
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (RFA DA 15 017) also looked into and applied for these:
| Funding Opportunity |
|---|
| Assay Validation For High Quality Markers For NCI Supported Clinical Trials (UH2/UH3) Apply for PAR 15 095 Funding Number: PAR 15 095 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Assay Validation For High Quality Markers For NCI Supported Clinical Trials (UH3) Apply for PAR 15 096 Funding Number: PAR 15 096 Agency: National Institutes of Health Category: Education Health Funding Amount: $250,000 |
| Prevention Research in Mid Life Adults (R21) Apply for PA 15 097 Funding Number: PA 15 097 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Prevention Research in Mid Life Adults (R01) Apply for PA 15 098 Funding Number: PA 15 098 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Reductions in Illicit Drug Use and Functional Outcomes (R21/R33) Apply for PA 15 099 Funding Number: PA 15 099 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Maternal Nutrition and Pre pregnancy Obesity Effects on Mothers, Infants and Children (R01) Apply for PA 15 100 Funding Number: PA 15 100 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Core Infrastructure and Methodological Research for Cancer Epidemiology Cohorts (U01) Apply for PAR 15 104 Funding Number: PAR 15 104 Agency: National Institutes of Health Category: Education Health Funding Amount: $2,500,000 |
| Comprehensive Partnerships to Advance Cancer Health Equity (CPACHE) (U54) Apply for PAR 15 103 Funding Number: PAR 15 103 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Developing Technologies and Tools to Monitor HIV Brain Reservoirs and How They May be Altered by Exposure to Substances of Abuse (R21/R33) Apply for RFA DA 15 018 Funding Number: RFA DA 15 018 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Gene Environment Interplay in Substance Use Disorders (R01) Apply for PA 15 110 Funding Number: PA 15 110 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Gene Environment Interplay in Substance Use Disorders (R03) Apply for PA 15 111 Funding Number: PA 15 111 Agency: National Institutes of Health Category: Education Health Funding Amount: $50,000 |
| Gene Environment Interplay in Substance Use Disorders (R21) Apply for PA 15 112 Funding Number: PA 15 112 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Advancing Exceptional Research on HIV/AIDS and Substance Abuse (R01) Apply for RFA DA 16 001 Funding Number: RFA DA 16 001 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| NIDA Mentored Clinical Scientists Development Program Award in Drug Abuse and Addiction (K12) Apply for PAR 15 119 Funding Number: PAR 15 119 Agency: National Institutes of Health Category: Education Health Funding Amount: $500,000 |
| Identification of Genetic and Genomic Variants by Next Gen in Sequencing Non human Animal Models (U01) Apply for PAR 15 120 Funding Number: PAR 15 120 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| BRAIN Initiative Optimization of Novel Tools and Technologies for Neuroscience Research (R44) Apply for PAR 15 121 Funding Number: PAR 15 121 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Functional Wellness in HIV Maximizing the Treatment Cascade (R01) Apply for PA 15 133 Funding Number: PA 15 133 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Functional Wellness in HIV Maximizing the Treatment Cascade (R21) Apply for PA 15 134 Funding Number: PA 15 134 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Administrative Supplements for Research on HIV/AIDS and Aging (Admin Supp) Apply for PA 15 137 Funding Number: PA 15 137 Agency: National Institutes of Health Category: Education Health Funding Amount: $100,000 |
| SBIR Phase IIB Bridge Awards to Accelerate the Development of Cancer Therapeutics, Imaging Technologies, Interventional Devices, Diagnostics and Prognostics Toward Commercialization (R44) Apply for RFA CA 15 010 Funding Number: RFA CA 15 010 Agency: National Institutes of Health Category: Education Health Funding Amount: $1,000,000 |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "RFA DA 15 017", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.